アブストラクト
| Title | HIF-PH阻害薬 - 腎性貧血 |
|---|---|
| Subtitle | 特集 心腎連関から新薬まで! 心×腎疾患の薬物治療 心腎領域の新薬 |
| Authors | 山崎智貴, 田中哲洋, 三村維真理 |
| Authors (kana) | |
| Organization | 東京大学医学部附属病院腎臓・内分泌内科 |
| Journal | 月刊薬事 |
| Volume | 64 |
| Number | 4 |
| Page | 768-773 |
| Year/Month | 2022 / 3 |
| Article | 報告 |
| Publisher | じほう |
| Abstract | [Points]●HIF-PH阻害薬は, 血液透析患者, 保存期腎不全患者への腎性貧血の治療薬として, 現在までに5剤が国内で販売を開始している. ●HIF-PH阻害薬は, 赤血球造血刺激因子製剤(ESA)が抱えていた高用量使用による副作用や, ESA低反応性貧血などの問題を, 生理的なエリスロポエチン(EPO)上昇と鉄動態の改善にて解決することが期待されている薬剤である. ●多くの大規模臨床試験で, HIF-PH阻害薬は貧血改善と鉄動態改善効果を示しているが, 合併症として血栓塞栓症, 悪性腫瘍や網膜症の悪化, 肺高血圧症などの多くの懸念事項が指摘されている. ●臨床運用では, 鉄動態の推移をフォローすることが最も肝要であり, 鉄欠乏所見が出現した場合には速やかに経口での鉄補充を検討すべきである. |
| Practice | 薬学 |
| Keywords |
- 全文ダウンロード： 従量制、基本料金制の方共に803円(税込) です。
参考文献
- 1) Pfeffer MA, et al : A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med, 361 : 2019-2032, 2009
- 2) Singh AK, et al : Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med, 355 : 2085-2098, 2006
- 3) Phrommintikul A, et al : Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin : a meta-analysis. Lancet, 369 : 381-388, 2007
- 4) Lando D, et al : Asparagine hydroxylation of the HIF trans-activation domain a hypoxic switch. Science, 295 : 858-861, 2002
- 5) Aeberhard JM, et al : Multiple site estimates of erythropoietin and renin in polycythemic kidney transplant patients. Transplantation, 50 : 613-616, 1990
残りの22件を表示する
- 6) Paliege A, et al : Hypoxia-inducible factor-2alpha-expressing interstitial fibroblasts are the only renal cells that express erythropoietin under hypoxia-inducible factor stabilization. Kidney Int, 77 : 312-318, 2010
- 7) Kojima I, et al : Protective role of hypoxia-inducible factor-2alpha against ischemic damage and oxidative stress in the kidney. J Am Soc Nephrol, 18 : 1218-1226, 2007
- 8) Mastrogiannaki M, et al : HIF-2alpha, but not HIF-1alpha, promotes iron absorption in mice. J Clin Invest, 119 : 1159-1166, 2009
- 9) Chen N, et al : Roxadustat for anemia in patients with kidney disease not receiving dialysis. N Engl J Med, 381 : 1001-1010, 2019
- 10) Chen N, et al : Roxadustat treatment for anemia in patients undergoing long-term dialysis. N Engl J Med, 381 : 1011-1022, 2019
- 11) Akizawa T, et al : Efficacy and safety of daprodustat compared with darbepoetin alfa in Japanese hemodialysis patients with anemia : A randomized, double-blind, phase 3 trial. Clin J Am Soc Nephrol, 15 : 1155-1165, 2020
- 12) Nangaku M, et al : Daprodustat compared with epoetin beta pegol for anemia in Japanese patients not on dialysis : A 52-week randomized open-label phase 3 trial. Am J Nephrol, 52 : 26-35, 2021
- 13) Nangaku M, et al : A phase 3, open-label, single-arm study of vadadustat for anemia in chronic kidney disease for Japanese patients on hemodialysis not receiving erythropoiesis-stimulating agents. Ther Apher Dial, 26 : 45-54, 2022
- 14) Nangaku M, et al : Phase 3 randomized study comparing vadadustat with darbepoetin alfa for anemia in Japanese patients with nondialysis-dependent CKD. J Am Soc Nephrol, 32 : 1779-1790, 2021
- 15) Nangaku M, et al : Efficacy and safety of vadadustat com-pared with darbepoetin alfa in Japanese anemic patients on hemodialysis : a Phase 3, multicenter, randomized, double-blind study. Nephrol Dial Transplant, 36 : 1731-1741, 2021
- 16) Eckardt KU, et al : Safety and efficacy of vadadustat for anemia in patients undergoing dialysis. N Engl J Med, 384 : 1601-1612, 2021
- 17) Chertow GM, et al : Vadadustat in patients with anemia and non-dialysis-dependent CKD. N Engl J Med, 384 : 1589-1600, 2021
- 18) Akizawa T, et al : Molidustat for anemia correction in Japanese patients undergoing hemodialysis : a single-arm, phase 3 study. Ther Apher Dial, 25 : 917-925, 2021
- 19) Yamamoto H, et al : Efficacy and safety of molidustat for anemia in ESA-naive nondialysis patients : A randomized, phase 3 trial. Am J Nephrol, 52 : 871-883, 2021
- 20) Yamamoto H, et al : Molidustat for renal anemia in non-dialysis patients previously treated with erythropoiesis-stim-ulating agents : A randomized, open-label, phase 3 study. Am J Nephrol, 52 : 884-893, 2021
- 21) Akizawa T, et al : Two long-term phase 3 studies of enarodustat(JTZ-951)in Japanese anemic patients with chronic kidney disease not on dialysis or on maintenance hemodialysis : SYMPHONY ND-Long and HD-Long studies. Ther Apher Dial, 2021(doi : 10.1111/1744-9987.13724)
- 22) Akizawa T, et al : A phase 3 study of enarodustat in anemic patients with CKD not requiring dialysis : The SYMPHONY ND study. Kidney Int Rep, 6 : 1840-1849, 2021
- 23) Status on FDA Advisory Committee vote on roxadustat in anaemia of chronic kidney disease. 2021(https://www.astrazeneca.com/media-centre/press-releases/2021/status-on-us-fda-advisory-committee-for-roxadustat.html)
- 24) Meijer TW, et al : Targeting hypoxia, HIF-1, and tumor glucose metabolism to improve radiotherapy efficacy. Clin Cancer Res, 18 : 5585-5594, 2012
- 25) Comerford KM, et al : Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance(MDR1)gene. Cancer Res, 62 : 3387-3394, 2002
- 26) Kraus A, et al : HIF-1α promotes cyst progression in a mouse model of autosomal dominant polycystic kidney disease. Kidney Int, 94 : 887-899, 2018
- 27) 日本腎臓学会 : HIF-PH阻害薬適正使用に関するrecommen-dation. 日本腎臓学会誌, 62 : 711-716, 2020
